ZVRA acquires ACER for_$1.85/sh_in_stock+CVR—a 203% premium to yesterday’s close (excluding the CVR): https://finance.yahoo.com/news/zevra-therapeutics-acquire-acer-therapeutics-113000961.html The nominal deal value (excluding the CVR) is $15M. ACER also announced that it bought back the commercial rights to Olpruva from RLF.SX.